Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Metacare Co's Net Income for the
three
months ended in Jun. 2026 was ₩412 Mil. Metacare Co's Revenue for the
three
months ended in Jun. 2026 was ₩8,761 Mil. Therefore, Metacare Co's net margin for the quarter that ended in Jun. 2026 was 4.71%.
The historical rank and industry rank for Metacare Co's Net Margin % or its related term are showing as below:
XKRX:118000'
s Net Margin % Range Over the Past 10 Years
Min: -259.47 Med: -8.36 Max: 169.95
Current: -3.99
XKRX:118000's Net Margin % is ranked worse than 69.89% of 963
companies
in the Drug Manufacturers industry
Industry Median: 5.11
vs XKRX:118000: -3.99
Metacare Co (XKRX:118000) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Metacare Co Net Margin % Related Terms
Metacare Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Metacare Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:118000 vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Metacare Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metacare Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Metacare Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Metacare Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metacare Co (XKRX:118000) has a Net Margin % of 4.71% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Metacare Co and its competitors. According to the industry distribution chart, Metacare Co ranks #673 out of 963 companies in the Drug Manufacturers industry, placing it in the top 69.9%.
Is Metacare Co's Net Margin % too high?
Metacare Co's current Net Margin % is 4.71%. The Drug Manufacturers industry median Net Margin % is 5.11. Metacare Co's value of 4.71% is 7.8% below this industry median. Based on the distribution chart, Metacare Co ranks #673 out of 963 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Metacare Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Metacare Co's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Metacare Co ranks #673 out of 963 companies for Net Margin %. This places Metacare Co in the lower half of its industry. The industry median Net Margin % is 5.11. Metacare Co's value of 4.71% is 7.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.11, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metacare Co's current Net Margin % of 4.71% is 7.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Metacare Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metacare Co's current Net Margin % is 4.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metacare Co stock overvalued right now?
Based on GuruFocus' analysis, Metacare Co (XKRX:118000) is currently considered Possible Value Trap. The stock's GF Value™ is ₩5,177.27, compared to a current price of ₩1,328.00 — trading 74.3% below its estimated fair value. The current Net Margin % is 4.71% and 7.8% below the Drug Manufacturers industry median of 5.11. Metacare Co's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Metacare Co (XKRX:118000), the current Net Margin % is 4.71% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metacare Co (XKRX:118000) Overvalued in 2026?
Based on GuruFocus' analysis, Metacare Co stock appears to be undervalued.
The current stock price of ₩1,328.00 is trading 74.3% below its estimated GF Value™ of ₩5,177.27.
GuruFocus considers Metacare Co to be Possible Value Trap.
Key valuation signals for XKRX:118000:
Net Margin %: 4.71%
GF Value™: ₩5,177.27 vs. price of ₩1,328.00 (74.3% below fair value)
Industry Position: 7.8% below the Drug Manufacturers median (#673 of 963)
No single metric tells the full story. See the XKRX:118000 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metacare Co Ltd formerly Smedi Co Ltd has established a hospital in Jeju and exports various types of medical equipments. The company also built its own hospital in China and India and plans to expand its business in Spain and Dubai. The Company and its subsidiaries are divided into pharmaceutical business, medical business, wireless device business, investment and others according to business characteristics by business sector.
42GF Score
Get the complete analysis for XKRX:118000
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:118000 has been successfully added to your 
